New York Medical Cannabis Fees Are Becoming A Market Stress Test
Cannabis operators reviewing paperwork tied to New York medical cannabis conversion fees.
New York medical cannabis fees are now becoming a serious market pressure point. MJBizDaily reports that New York’s vertically integrated medical cannabis operators owe up to $15 million each in conversion fees tied to entering the adult use market. Those operators are asking the state to reduce or eliminate the fee, arguing that medical cannabis sales are falling, dispensaries are closing, and three of the state’s 10 original registered organizations have already gone out of business. For operators, investors, lenders, landlords, and compliance teams, this is not just a fee dispute. It is a warning about what happens when market access costs collide with declining revenue.
Quick facts
• New York medical cannabis operators owe up to $15 million each in adult use conversion fees
• The fee was originally set at $20 million before being reduced to $15 million
• Medical operators argue the fee is no longer realistic under current market conditions
• MJBizDaily reports that three of the state’s 10 original registered organizations have gone out of business
• New York medical cannabis sales fell from $162.1 million in 2023 to $139.1 million in 2024, then $95.5 million through November 2025
• New York had 31 open medical dispensaries as of November 30, 2025, according to OCM’s 2025 annual report
• The universal operator lesson is simple: market access fees can become dangerous when revenue, patient access, and cash flow are moving the wrong way
If New York fee pressure is affecting your growth plan, complete our quick Cannashield intake form so you can map licensing, financial, and insurance exposure before conversion costs create a bigger business problem.
Why the conversion fee matters
The $15 million conversion fee was built around a specific policy idea. New York wanted to let medical cannabis operators enter the adult use market while also protecting the rollout for smaller operators. The fee was also supposed to support market development and help fund resources for operators who did not have the same capital base as large medical companies.
That concept made sense politically. The problem is that the market changed. Medical cannabis operators are now arguing that the economics no longer support the fee. Medical sales have dropped, dispensaries have closed, and adult use stores are pulling customers away from the medical channel.
Why falling medical sales change the equation
New York’s own annual report shows the pressure clearly. Medical cannabis sales fell from $162.1 million in 2023 to $139.1 million in 2024, then $95.5 million through November 2025. At the same time, adult use sales grew sharply.
That creates a difficult position for medical operators. They are being asked to pay a major access fee while the medical side of the business is weakening. A fee that may have looked manageable during stronger valuation periods can become much harder when patient counts fall, stores close, and operators need capital to compete in adult use.
This is the universal operator lesson. A license fee is not just a government charge. It is a capital allocation decision. If the fee is too high relative to the market opportunity, it can weaken the very operators the state expects to support access.
If uncertainty around licensing fees, adult use access, or medical sales pressure is affecting how you plan, complete our Cannashield questionnaire to pressure test your exposure before market access turns into cash strain.
Why small operators are pushing back
Adult use operators have a different concern. Many of them argue that the conversion fees were part of the original market bargain. Those fees were expected to support equity operators, strengthen the supply chain, and help fight illicit competition.
From their perspective, reducing or eliminating the fees now could feel like changing the rules after smaller operators already struggled through the rollout. Many adult use businesses had to fight for real estate, financing, vendors, and customers without the support they expected.
That is the tension. Medical operators say the fee no longer matches market reality. Smaller operators say the fee was part of the state’s promise to build a fairer market. Both sides are pointing to real problems. The state now has to decide whether the fee protects the market or adds more pressure to it.
Why lenders and landlords should care
This story is not only for license holders. Lenders and landlords should pay close attention because conversion fees, declining medical sales, and adult use competition all affect tenant stability and borrower strength.
A medical operator that owes millions in fees may delay expansion, close locations, reduce staffing, renegotiate leases, or seek relief from the state. A landlord may see a licensed tenant and assume stability, but the balance sheet may tell a different story. A lender may see adult use access as upside, but that upside depends on fee burden, store performance, and whether the operator can actually afford the transition.
If you need to organize license, lease, fee, and insurance records before a financing or renewal conversation, use the Cannashield intake form to identify weak points and build a clearer risk picture.
You might also like
Conclusion
New York’s medical cannabis conversion fee fight shows how complicated market design becomes once real economics take over. The state wanted to balance medical operators, adult use access, small business development, and illicit market enforcement. Now the fee structure itself is becoming a stress test.
For operators, investors, lenders, and landlords, the message is simple. Do not treat license access as guaranteed value. Fees, sales trends, store count, patient access, and capital strain all decide whether that access can be converted into a sustainable business.
Educational note: This article is for education only and is not legal, regulatory, financial, tax, or insurance advice.
What To Do This Week
• Review all license fees, milestone payments, and state obligations tied to adult use access
• Compare fee obligations against current medical and adult use revenue
• Track patient counts, store closures, and per store sales trends
• Review lease, debt, and investor documents for pressure tied to unpaid fees
• Build a plan for fee relief, payment timing, or capital reserve needs
• Prepare a short memo on how fee pressure could affect operations over the next 12 months
FAQ
What is the New York conversion fee?
It is a fee medical cannabis registered organizations owe as a condition of entering New York’s adult use market.
How much do operators owe?
MJBizDaily reports that vertically integrated medical cannabis operators owe up to $15 million each.
Why are operators asking for relief?
They argue that medical cannabis sales are falling, dispensaries are closing, and the fee no longer fits current market conditions.
Why do adult use operators oppose relief?
Some adult use operators argue the fees were supposed to support market development, equity operators, and illicit market enforcement.
How much have medical sales declined?
OCM data cited in MJBizDaily and the state annual report show medical sales falling from $162.1 million in 2023 to $139.1 million in 2024, then $95.5 million through November 2025.
What is the biggest operator takeaway?
Market access fees can become serious business risk when revenue, patient access, and cash flow are weakening.
SOURCES
MJBizDaily, New York medical cannabis operators owe the state millions they claim they can’t afford
https://mjbizdaily.com/news/new-york-medical-cannabis-operators-owe-the-state-millions-they-claim-they-cant-afford/616246/
New York Office of Cannabis Management, 2025 Annual Report
https://cannabis.ny.gov/system/files/documents/2025/12/ocm-annual-report_final-2025.pdf
New York Office of Cannabis Management, Registered Organization Adult Use Licensing Communication
https://cannabis.ny.gov/system/files/documents/2023/10/ro-communication-transition-to-rod-or-rond-license.pdf
Japan has banned CBN after reported hospitalizations and health concerns, prohibiting production, sale, possession, and use of the cannabinoid. The bigger lesson for operators is that international cannabinoid markets can change fast, making product legality, health claims, and import controls real market access risks.